<DOC>
	<DOCNO>NCT02872259</DOCNO>
	<brief_summary>The purpose study assess safety efficacy BGB324 give together standard treatment , pembrolizumab dabrafenib trametinib , compare standard treatment alone ,</brief_summary>
	<brief_title>BGB324 Combination With Pembrolizumab Dabrafenib/Trametinib Metastatic Melanoma</brief_title>
	<detailed_description>This investigator initiate randomized randomized clinical phase 1b/2 clinical trial compare safety efficacy Axl inhibitor BGB324 combination pembrolizumab dabrafenib+trametinib pembrolizumab dabrafenib+trametinib alone . Patients non-resectable stage III stage IV melanoma stratify base BRAF mutation tumor load start dabrafenib+trametinib ( BRAF mutation high tumor load ) pembrolizumab ( BRAF wild type BRAF mutation low tumor load ) first line . The patient randomize 2:1 receive BGB324 combination pembrolizumab dabrafenib+trametinib receive pembrolizumab dabrafenib+trametinib alone . A 3+3 dose escalation perform combination BGB324 dabrafenib+trametinib . There major focus predictive marker treatment response evaluate blood sample biopsy .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>1 . Patients able understand willing sign write protocol specific inform consent 18 year old time consent 2 . Histologically confirm advanced cutaneous melanoma either nonresectable ( Stage IIIc ) metastatic ( Stage IV ) : 1 . At least one measurable lesion define RECIST 1.1 CT MRI scan 2 . Documented progression ≥1 measurable lesion 3 . ECOG score 0 2 screen 4 . Availability fresh archival tumour tissue sample suitable evaluation predictive biomarkers response 5 . Male patient female partner childbearing potential female patient childbearing potential willing practice highly effective birth control screening , throughout study least 3 month follow last dose study treatment ( female childbearing potential , negative serum pregnancy test 7 day first dose study treatment ) 1 . Prior first line systemic treatment treatment Stage IIIb Stage IIIc melanoma , include BRAF MEK inhibitor ( adjuvant immunomodulating agent treatment 6 month prior first dose study treatment allow ) 2 . Symptomatic central nervous system metastatic lesion determine Investigator ( patient radiographically stable , asymptomatic lesion previously irradiate surgically resect eligible provide need systemic corticosteroid treatment complete least 4 week first dose study treatment ) 3 . History malignancy melanoma within last 2 year ( basal squamous cell carcinoma skin carcinoma situ cervix ; isolate elevation prostate specific antigen absence histological radiographic evidence prostate cancer allow ) 4 . History current active autoimmune disease , include limited inflammatory bowel disease , rheumatoid arthritis , autoimmune thyroiditis , autoimmune hepatitis , systemic sclerosis ( scleroderma variant ) , systemic lupus erythematosus , autoimmune vasculitis , autoimmune neuropathy ( e.g . GuillainBarré syndrome ) . Patients vitiligo , nonserious autoimmune disease base Investigator 's assessment , NOT exclude 5 . History follow cardiac condition : 1 . Congestive cardiac failure &gt; Grade 2 severity ( see Appendix 1 ) accord New York Heart Association ( define symptomatic less ordinary level activity ) 2 . Ischemic cardiac event include myocardial infarction within 3 month prior first dose study treatment 3 . Uncontrolled cardiac disease , include unstable angina , uncontrolled hypertension ( i.e . sustain systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 90 mmHg ) , need change medication within 6 week provision consent due lack disease control 4 . History presence sustain bradycardia ( ≤55 bpm ) , leave bundle branch block , cardiac pacemaker ventricular arrhythmia . Note : Patients supraventricular arrhythmia require medical treatment , normal ventricular rate eligible 5 . Family history long QTc syndrome ; personal history long QTc syndrome previous druginduced QTc prolongation 6 . Abnormal leave ventricular ejection fraction echocardiography Multi Gated Acquisition ( MUGA ) scan ( less low limit normal patient age treat institution &lt; 45 % , whichever low ) 7 . Current treatment agent know cause Torsade de Points discontinue least five halflives two week prior first dose study treatment 8 . Screening 12lead ECG measurable QTc interval calculate accord Fridericia 's correction ( QTcF ) &gt; 450 m 9 . Inadequate organ function define follow laboratory value : 1 . Haematological : absolute neutrophil count ≤1.5 x 109/L , platelet ≤100 x 109/L , haemoglobin ≤9.0 g/dL 2 . Renal : serum creatinine ≥1.5 x institutional upper limit normal ( ULN ) creatinine clearance ≥50 mL/minute 3 . Hepatic : total bilirubin ≥1.5 x institutional ULN , alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≥2.5 x institutional ULN ≥5.0 x institutional ULN liver metastases present 4 . Coagulation : international normalised ratio prothrombin time activate partial thromboplastin time ≥1.5 x institutional ULN use anticoagulant ( patient receive anticoagulant therapy value must within therapeutic range condition treat ) 10 . Ongoing infection require systemic treatment . Patients prophylactic anti infectives afebrile 48 hour follow initiation treatment eligible 11 . Known active infection human immunodeficiency virus ( HIV ) , hepatitis B C virus ( screen require ) Patients history hepatitis B infection eligible provide hepatitis B surface antigen negative Patients history hepatitis C infection eligible provide evidence hepatitis C ribonucleic acid use quantitative polymerase chain reaction assay least 6 month complete treatment hepatitis C infection 12 . Any condition may significant impact absorption BGB324 dabrafenib gastrointestinal tract ( include limit , celiac disease Crohn 's disease , gastric bowel resection ) 13 . Any severe uncontrolled medical condition may jeopardise patient safety , compliance protocol , interpretation study result opinion Investigator 14 . Current recent ( within last year ) systemic treatment immunosuppressive immunomodulating agent ( include systemic steroid intend immunosuppressive effect ) , medication know significant impact immune system . Topical agent inhaled steroid permit 15 . Treatment medication narrow therapeutic index predominantly metabolise cytochrome P450 ( CYP ) 3A4 stop first dose study treatment 16 . Known hypersensitivity pembrolizumab , trametinib dabrafenib BGB324 excipients ( include lactose intolerance ) 17 . Treatment histamine receptor 2 inhibitor , proton pump inhibitor antacids 7 day first dose study treatment 18 . History retinal vein occlusion ongoing retinal pigment epithelial detachment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>metastatic melanoma</keyword>
	<keyword>advanced Non-resectable melanoma</keyword>
</DOC>